Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2009-03-11
2011-10-04
Vivlemore, Tracy (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S024500
Reexamination Certificate
active
08030291
ABSTRACT:
The invention provides antisense antiviral compounds and methods of their use and production in inhibition of growth of viruses of the Filoviridae family, and in the treatment of a viral infection. The compounds and methods relate to the treatment of viral infections in mammals including primates by Ebola and Marburg viruses. The antisense antiviral compounds are morpholino oligonucleotides having: a) a nuclease resistant backbone, b) 15-40 nucleotide bases, and c) a targeting sequence of at least 15 bases in length that hybridizes to a target region selected from the following: i) the Ebola virus AUG start site region of VP24; ii) the Ebola virus AUG start site region of VP35; iii) the Marburg virus AUG start site region of VP24; or iv) the Marburg virus AUG start site region of NP.
REFERENCES:
patent: 5034506 (1991-07-01), Summerton et al.
patent: 5142047 (1992-08-01), Summerton et al.
patent: 5166315 (1992-11-01), Summerton et al.
patent: 5185444 (1993-02-01), Summerton et al.
patent: 5194428 (1993-03-01), Agrawal et al.
patent: 5217866 (1993-06-01), Summerton et al.
patent: 5495006 (1996-02-01), Climie et al.
patent: 5506337 (1996-04-01), Summerton et al.
patent: 5521063 (1996-05-01), Summerton et al.
patent: 5576302 (1996-11-01), Cook et al.
patent: 5580767 (1996-12-01), Cowsert et al.
patent: 5698685 (1997-12-01), Summerton et al.
patent: 5702891 (1997-12-01), Kolberg et al.
patent: 5734039 (1998-03-01), Calabretta et al.
patent: 5738985 (1998-04-01), Miles et al.
patent: 5749847 (1998-05-01), Zewert et al.
patent: 5801154 (1998-09-01), Baracchini et al.
patent: 5892023 (1999-04-01), Pirotzky et al.
patent: 5955318 (1999-09-01), Simons et al.
patent: 5989904 (1999-11-01), Das et al.
patent: 6060456 (2000-05-01), Arnold, Jr. et al.
patent: 6133246 (2000-10-01), McKay et al.
patent: 6174868 (2001-01-01), Anderson et al.
patent: 6214555 (2001-04-01), Leushner et al.
patent: 6228579 (2001-05-01), Zyskind et al.
patent: 6239265 (2001-05-01), Cook
patent: 6258570 (2001-07-01), Glustein et al.
patent: 6306993 (2001-10-01), Rothbard et al.
patent: 6365351 (2002-04-01), Iversen
patent: 6365577 (2002-04-01), Iversen
patent: 6391542 (2002-05-01), Anderson et al.
patent: 6495663 (2002-12-01), Rothbard et al.
patent: 6667152 (2003-12-01), Miles et al.
patent: 6669951 (2003-12-01), Rothbard et al.
patent: 6677153 (2004-01-01), Iversen
patent: 6784291 (2004-08-01), Iversen et al.
patent: 6828105 (2004-12-01), Stein et al.
patent: 6841542 (2005-01-01), Bartelmez et al.
patent: 6841675 (2005-01-01), Schmidt et al.
patent: 6881825 (2005-04-01), Robbins et al.
patent: 7049431 (2006-05-01), Iversen et al.
patent: 7094765 (2006-08-01), Iversen et al.
patent: 7115374 (2006-10-01), Linnen et al.
patent: 7507196 (2009-03-01), Stein et al.
patent: 7524829 (2009-04-01), Stein et al.
patent: 2003/0095953 (2003-05-01), Cabot et al.
patent: 2003/0166588 (2003-09-01), Iversen et al.
patent: 2003/0171311 (2003-09-01), Blatt et al.
patent: 2003/0171335 (2003-09-01), Stein et al.
patent: 2003/0175767 (2003-09-01), Davis et al.
patent: 2003/0224353 (2003-12-01), Stein et al.
patent: 2004/0072239 (2004-04-01), Renaud et al.
patent: 2004/0259108 (2004-12-01), Linnen et al.
patent: 2005/0176661 (2005-08-01), Vaillant et al.
patent: 2006/0063150 (2006-03-01), Iversen et al.
patent: 2006/0149046 (2006-07-01), Arar
patent: 2006/0269911 (2006-11-01), Iversen et al.
patent: 2007/0066556 (2007-03-01), Stein et al.
patent: 2007/0129323 (2007-06-01), Stein et al.
patent: 2007/0265214 (2007-11-01), Stein et al.
patent: 2009/0088562 (2009-04-01), Weller et al.
patent: WO 98/12312 (1998-03-01), None
patent: WO 00/00617 (2000-01-01), None
patent: WO 02/26968 (2002-04-01), None
patent: WO 02/068637 (2002-09-01), None
patent: WO 03/033657 (2003-04-01), None
patent: WO 2005/007805 (2005-01-01), None
patent: WO 2005/013905 (2005-02-01), None
patent: WO 2005/030800 (2005-04-01), None
patent: WO 2006/047683 (2006-04-01), None
Swenson et al. Antimicrobial Agents and Chemotherapy 2009, vol. 53, pp. 2089-2099.
Warfield et al. PLoS Pathogens 2006, vol. 2, pp. 5-13.
Warren et al. Nature Medicine 2010, vol. 16, pp. 991-994.
Fowler et al., “Inhibition of Marburg virus protein expression and viral release by RNA interference,” Journal of General Virology 86:1181-1188, 2005.
GenBank Accession No. AF086833, “Zaire Ebola virus strain Mayinga, complete genome,” retrieved Aug. 11, 2010, from http://www.ncbi.nlm.nih.gov
uccore/10141003, 9 pages.
GenBank Accession No. AF522874, “Reston Ebola virus strain Pennsylvania, complete genome,” retrieved Aug. 11, 2010, 8 pages.
GenBank Accession No. Z29337, “Marburg virus (Popp) NP, VP35, VP40, GP, VP30, VP24, L genes,” retrieved Aug. 11, 2010, 8 pages.
International Search Report for International Application No. PCT/US2005/039607, mailed Aug. 29, 2007, 4 pages.
Iversen et al., “Antisense Antiviral Compound and Method for Treating ssRNA Viral Infection,” Office Action mailed Oct. 19, 2010, for U.S. Appl. No. 11/432,031, 25 pages.
Stein et al., “Antisense Antiviral Agent and Method for Treating ssRNA Viral Infection,” Office Action mailed Feb. 17, 2010, for U.S. Appl. No. 11/431,968, 19 pages.
Warfield et al., “Development of a Phoshorodiamidate Morpholino Oligomer Antisense to Ebola Zaire” Antiviral Research 63(5): A45, 2005.
Written Opinion for International Application No. PCT/US2005/039607, mailed Aug. 29, 2007, 6 pages.
Agrawal et al., “Antisense Therapeutics: Is it as Simple as Complementary Base Recognition?”,Molecular Medicine Today, 6:72-81 (2000).
Agrawal et al. “Oligodeoxynucleoside phosphoramidates and phosphorothioates as inhibitors of human immunodeficiency virus”,Proc Natl Acad Sci U S A., 85(19):7079-7083 (1988).
Agrawal et al. “Site-specific excision from RNA by RNase H and mixed-phosphate-backbone oligodeoxynucleotides”,Proc Natl Acad Sci U S A., 87(4):1401-5 (1990).
Arora and Iversen, “Redirection of drug metabolism using antisense technology”,Curr. Opin Mol. Ther., 3(3):249-257 (2001).
Bailey, C. P., J. M. Dagle et al., “Cationic oligonucleotides can mediate specific inhibition of gene expression inXenopus oocytes.” Nucleic Acids Res, 26(21): 4860-7 (1998).
Banerjee, R. and A. Dasgupta, “Interaction of picornavirus 2C polypeptide with the viral negative-strand RNA.”Journal of General Virology, 82(Pt 11): 2621-7 (2001).
Banerjee, R. and A. Dasgupta, “Specific interaction of hepatitis C virus protease/helicase NS3 with the 3′-terminal sequences of viral positive- and negative-strand RNA.”Journal of Virology, 75(4): 1708-21 (2001).
Banerjee, R., A. Echeverri, et al. “Poliovirus-encoded 2C polypeptide specifically binds to the 3′-terminal sequences of viral negative-strand RNA.”Journal ofVirology, 71(12): 9570-8 (1997).
Banerjee, R., W. Tsai, et al., “Interaction of poliovirus-encoded 2C/2BC polypeptides with the 3′ terminus negative-strand cloverleaf requires an intact stem-loop b.”Virology, 280(1): 41-51 (2001).
Barawkar, D. A. and T. C. Bruice, “Synthesis, biophysical properties, and nuclease resistance properties of mixed backbone oligodeoxynucleotides containing cationic internucleoside guanidinium linkages: deoxynucleic guanidine/DNA chimeras.”Proc Natl Acad Sci U S A, 95(19): 11047-52. (1998).
Basler et al., “The Ebola virus VP35 protein functions as a type I IFN antagonist”,Proc. Natl. Acad. Sci. U.S.A., 97(22):12289-12294 (2000).
Blommers, M. J., U. Pieles, et al., “An approach to the structure determination of nucleic acid analogues hybridized to RNA. NMR studies of a duplex between 2′- OMe RNA and an oligonucleotide containing a single amide backbone modification.”Nucleic Acids Res 22(20): 4187-94 (1994).
Bonham et al., “An assessment of the antisense properties of RNase H-competent and steric-blocking oligomers”,Nucleic Acids Res., 23(7):1197-203 (1995).
Borio, L. et
Bavari Sina
Iversen Patrick L.
Stein David A.
Weller Dwight D.
AVI BioPharma Inc.
Seed IP Law Group PLLC
U.S. Army Medical Research and Material Command
Vivlemore Tracy
LandOfFree
Antisense antiviral compounds and methods for treating a... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antisense antiviral compounds and methods for treating a..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antisense antiviral compounds and methods for treating a... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4258591